PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Sarpagandha Ghana vati (500 mg twice daily for 30 days) was evaluated for efficacy in managing essential hypertension [PMID:29242090]. Another trial indicated that Sarpagandha Vati helped reduce systolic and diastolic pressures, though effects were less marked than Shirodhara therapy [PMID:22048535].
Ayurvedic herbal formulations such as Sarpagandha Vati have shown promise in reducing blood pressure [PMID:40264318].
Evidence summary
PubMed sources
- 1.PMID: 35819514 (2022) — Biotechnological interventions and indole alkaloid production in Rauvolfia serpentina. · Applied microbiology and biotechnology
- 2.PMID: 31363825 (2019) — Biotechnological interventions on the genus Rauvolfia: recent trends and imminent prospects. · Applied microbiology and biotechnology
- 3.PMID: 26798180 (2015) — Design, Development and Rationalization of Sarpagandha Ghanvati. · Indian journal of pharmaceutical sciences
- 4.PMID: 23458029 (2013) — Forensic identification of Indian snakeroot (Rauvolfia serpentina Benth. ex Kurz) using DNA barcoding. · Journal of forensic sciences
- 5.PMID: 38212296 (2024) — De novo biosynthesis of antiarrhythmic alkaloid ajmaline.